Current treatments

Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II…

Diagnostic techniques and prognostic indicators

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Horger M et al. Eur Radiol. 2016 Nov 23. [Epub ahead of print]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Predictors of inferior clinical outcome in patients with…

Related conditions

Plasma cell leukemia: update on biology and therapy. Mina R et al. Leuk Lymphoma. 2016 Nov 6:1-10. [Epub ahead of print]. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Maciocia N et al. Hematol Oncol. 2016 Nov 2. doi: 10.1002/hon.2345. [Epub ahead of print]. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition…

Emerging treatments

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma(MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R et al. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30165-X. doi: 10.1016/S2352-3026(16)30165-X. [Epub ahead of print]. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L et al. Br J Haematol. 2016…

Biology and genetics

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Li N et al. Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. Jiménez C et al. J Mol Diagn. 2016 Nov 15. pii: S1525-1578(16)30186-6. doi: 10.1016/j.jmoldx.2016.08.004. [Epub ahead of print]. Exome copy number variation detection:…

General

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Malard F et al. Cancer Treat Rev. 2016 Nov 15;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. [Epub ahead of print]. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Musto P et al. Ann Oncol. 2016 Nov 17. pii: mdw606. [Epub ahead of print]. Aging, ‘Treating the Older Patient’. Rosko A et al. Biol…

Supportive care

Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Isoda A et al. Int J Hematol. 2016 Nov 21. [Epub ahead of print]. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Kurtz JE et al. Onco Targets Ther. 2016 Oct 28;9:6689-6693. eCollection 2016. Percutaneous sacroplasty…

Complications of myeloma and its treatments

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients. Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print]. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print]. Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors. Jouni H et al. Am J…

Current treatments

Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print]. Absence…